© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
April 15, 2017
PARP inhibitors are an active, novel, and exciting class of anticancer agents. They have shown clear patient benefit in gBRCA, HR-deficient, and other ovarian cancers.